Lead Product(s) : Sodium Iodide
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study for ICU-Acquired Weakness
Details : Phase 1 data have demonstrated no signs of toxicity in healthy subjects, and a Phase 2 study suggested a reduction in infarct size and improved cardiac function in patients treated with FDY-5301 after suffering an acute myocardial infarction (AMI).
Product Name : FDY-5301
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2021
Lead Product(s) : Sodium Iodide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable